De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Repligen Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Olivier Loeillot
Algemeen directeur
US$5.4m
Totale compensatie
| Percentage CEO-salaris | 2.5% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 1.9yrs |
| Gemiddelde ambtstermijn bestuur | 8.6yrs |
Recente managementupdates
Recent updates
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price
Sep 08
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Jul 31We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt
Jul 15Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$2m |
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$5m | US$138k | US$42m |
Compensatie versus markt: De totale vergoeding ($USD 5.45M ) Olivier } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Olivier te vergelijken met de prestaties van het bedrijf.
CEO
Olivier Loeillot (54 yo)
less than a year
Tenure
US$5,445,065
Compensatie
Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chair | 9.4yrs | US$7.93m | 0.18% $ 13.9m | |
| President | less than a year | US$5.45m | geen gegevens | |
| CFO & Chief Compliance Officer | 1.1yrs | US$2.03m | geen gegevens | |
| Chief Operating Officer | 4.6yrs | US$3.74m | 0.0075% $ 575.8k | |
| Senior Vice President of Research & Development | 8yrs | US$1.66m | 0.010% $ 785.6k | |
| Chief Information Officer | no data | geen gegevens | geen gegevens | |
| Global Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Global Head of Legal | no data | geen gegevens | geen gegevens | |
| VP & Global Head of Sales | 2yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | 1.8yrs | geen gegevens | geen gegevens | |
| Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics | 4.8yrs | geen gegevens | geen gegevens | |
| Senior Director of Packaging & Sustainability | no data | geen gegevens | geen gegevens |
1.9yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RGEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chair | 9.4yrs | US$7.93m | 0.18% $ 13.9m | |
| President | less than a year | US$5.45m | geen gegevens | |
| Independent Director | 9yrs | US$322.84k | 0.022% $ 1.7m | |
| Member of Scientific Advisory Board | 8.6yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.7yrs | US$453.50k | 0.0070% $ 536.0k | |
| Lead Independent Director | 19.1yrs | US$431.12k | 0.16% $ 12.3m | |
| Member of Scientific Advisory Board | 8.6yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board & Independent Director | 8.6yrs | US$282.84k | 0.00095% $ 72.7k | |
| Member of Scientific Advisory Board | 8.6yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.6yrs | US$287.84k | 0.0042% $ 320.8k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 10.3yrs | US$307.84k | 0.0071% $ 542.1k |
8.6yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.6 jaar).